FDA
-
-
-
-
-
-
-
Timber Pharmaceuticals Provides Business Update and Announces Fourth Quarter and Year End 2022 Financial Results
-
-
-
-
-
-
-
Timber Pharmaceuticals Inc. (TMBR) Reports Publication of Results from Phase 2b CONTROL Study of TMB-001
-
-
-
-
-
-
-
Timber Pharmaceuticals Inc. (TMBR) Granted FDA Fast Track Designation for TMB-001 in Severe Subtypes of Congenital
-
-
-
-
-
-
-
Timber Pharmaceuticals Inc. (TMBR) Announces Positive End-of-Phase 2 Meeting with FDA for TMB-001
-
-
-
-
-
-
-
Timber Pharmaceuticals Inc. (TMBR) Reports Complete Patient Enrollment in Phase 2b CONTROL Study Evaluating TMB-001 in Congenital Ichthyosis
-
-
-
-
-
-
-
Pre-Open Stock Movers 01/13: (MTRX) (TMBR) (INTC) Higher; (MARA) (PRTY) (URBN) Lower (more...)
-
-
-
-
-
-
-
Timber Pharmaceuticals Announces All CONTROL Study Sites Open and Enrolling Patients with Moderate to Severe Congenital Ichthyosis
323,716 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

